CA2837341C - Method of determining vasoreactivity using inhaled nitric oxide - Google Patents

Method of determining vasoreactivity using inhaled nitric oxide Download PDF

Info

Publication number
CA2837341C
CA2837341C CA2837341A CA2837341A CA2837341C CA 2837341 C CA2837341 C CA 2837341C CA 2837341 A CA2837341 A CA 2837341A CA 2837341 A CA2837341 A CA 2837341A CA 2837341 C CA2837341 C CA 2837341C
Authority
CA
Canada
Prior art keywords
patient
vasoreactivity
determining
nitric oxide
inhaled nitric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2837341A
Other languages
English (en)
French (fr)
Other versions
CA2837341A1 (en
Inventor
Tammy WATTS
Robert F. Roscigno
David H. Fine
Lewis J. Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vero Biotech Inc
Original Assignee
Vero Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vero Biotech Inc filed Critical Vero Biotech Inc
Publication of CA2837341A1 publication Critical patent/CA2837341A1/en
Application granted granted Critical
Publication of CA2837341C publication Critical patent/CA2837341C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2837341A 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide Active CA2837341C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490929P 2011-05-27 2011-05-27
US61/490,929 2011-05-27
PCT/US2012/039401 WO2012166534A1 (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Publications (2)

Publication Number Publication Date
CA2837341A1 CA2837341A1 (en) 2012-12-06
CA2837341C true CA2837341C (en) 2021-10-19

Family

ID=47259769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837341A Active CA2837341C (en) 2011-05-27 2012-05-24 Method of determining vasoreactivity using inhaled nitric oxide

Country Status (6)

Country Link
US (1) US11154210B2 (cg-RX-API-DMAC7.html)
EP (1) EP2713723B1 (cg-RX-API-DMAC7.html)
JP (3) JP2014527025A (cg-RX-API-DMAC7.html)
AU (1) AU2012262534B2 (cg-RX-API-DMAC7.html)
CA (1) CA2837341C (cg-RX-API-DMAC7.html)
WO (1) WO2012166534A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2006023616A2 (en) * 2004-08-18 2006-03-02 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
AU2009209181B2 (en) 2008-01-28 2014-01-16 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
US8613958B2 (en) 2009-06-22 2013-12-24 Geno Llc Nitric oxide therapies
AU2012262534B2 (en) 2011-05-27 2016-06-02 VERO Biotech LLC. Method of determining vasoreactivity using inhaled nitric oxide
WO2015160777A1 (en) 2014-04-15 2015-10-22 Commscope Technologies Llc Wideband remote unit for distributed antenna system
PT3970730T (pt) * 2016-02-12 2024-07-30 Mallinckrodt Pharmaceuticals Ireland Ltd Sistema para utilização e monitorização de óxido nítrico inalado com dispositivos de ajuda ventricular esquerda
JP6704094B2 (ja) 2017-02-27 2020-06-03 サード ポール, インコーポレイテッドThird Pole, Inc. 酸化窒素を生成するためのシステムおよび方法
MX2019009931A (es) 2017-02-27 2020-07-14 Third Pole Inc Sistemas y metodos para generacion ambulatoria de oxido nitrico.
MX2020010523A (es) 2017-02-27 2021-02-09 Third Pole Inc Sistemas y metodos para generar oxido nitrico.
US11672938B1 (en) 2018-07-18 2023-06-13 Vero Biotech LLC Start-up protocols for nitric oxide delivery device
WO2020074957A1 (en) * 2018-10-12 2020-04-16 Sanotize Research And Development Corp. Gas-evolving compositions and container and delivery systems
WO2020232414A1 (en) 2019-05-15 2020-11-19 Third Pole, Inc. Architectures for production of nitric oxide
WO2020232419A1 (en) 2019-05-15 2020-11-19 Third Pole, Inc. Systems and methods for generating nitric oxide
EP3969415A4 (en) 2019-05-15 2023-08-16 Third Pole, Inc. ELECTRODES FOR GENERATING NITROUS OXIDE
EP4069069A4 (en) 2020-01-11 2024-07-03 Third Pole, Inc. SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL
EP4167920A4 (en) 2020-06-18 2024-06-12 Third Pole, Inc. Systems and methods for preventing and treating infections with nitric oxide
WO2022082072A1 (en) 2020-10-16 2022-04-21 Third Pole, Inc. Nitric oxide generation process controls
WO2023049873A1 (en) 2021-09-23 2023-03-30 Third Pole, Inc. Systems and methods for delivering nitric oxide
US12569628B2 (en) 2022-04-14 2026-03-10 Third Pole, Inc. Delivery of medicinal gas in a liquid medium

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6758214B2 (en) 2000-01-28 2004-07-06 Cyterra Corporation Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment
US7040313B2 (en) 2001-09-05 2006-05-09 Cyterra Corporation Method and apparatus for nitric oxide generation
US7618594B2 (en) 2004-08-18 2009-11-17 Geno Llc Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2006023616A2 (en) 2004-08-18 2006-03-02 Geno Llc Conversion of nitrogen dioxide (no2) to nitric oxide (no)
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
AU2008232413B2 (en) 2007-03-23 2013-09-19 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
AU2009209181B2 (en) 2008-01-28 2014-01-16 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
WO2010011928A1 (en) 2008-07-24 2010-01-28 Geno Llc Methods for diagnosing and treating a heart condition in a patient
US10780241B2 (en) 2008-08-21 2020-09-22 Vero Biotech LLC Devices and methods for minimizing and treating high-altitude sickness
US10960168B2 (en) 2008-08-21 2021-03-30 Vero Biotech LLC Delivery of high concentration nitric oxide
US8701657B2 (en) 2008-08-21 2014-04-22 Geno Llc Systems for generating nitric oxide
US8607785B2 (en) 2008-08-21 2013-12-17 Geno Llc Systems and devices for generating nitric oxide
EP2362810A4 (en) 2008-09-22 2013-09-11 Geno Llc CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITROGEN MONOXIDE (NO)
US8613958B2 (en) 2009-06-22 2013-12-24 Geno Llc Nitric oxide therapies
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
JP5995724B2 (ja) * 2009-11-20 2016-09-21 ゲノ エルエルシー 一酸化窒素送達システム
US20120093948A1 (en) * 2009-11-20 2012-04-19 Fine David H Nitric Oxide Treatments
WO2011137122A1 (en) 2010-04-26 2011-11-03 Geno Llc Nitrosyl special connector
CA2797702C (en) 2010-04-26 2020-03-10 VERO Biotech LLC. Delivery of ultra pure nitric oxide (no)
USD688352S1 (en) 2010-04-27 2013-08-20 Geno Llc Female gas connector
USD679366S1 (en) 2010-04-27 2013-04-02 Geno Llc Male gas connector
EP2645860A4 (en) * 2010-12-03 2014-07-09 Geno Llc NITROGEN OXIDE TREATMENTS
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
AU2012262534B2 (en) 2011-05-27 2016-06-02 VERO Biotech LLC. Method of determining vasoreactivity using inhaled nitric oxide
EP4180078A1 (en) 2014-10-20 2023-05-17 VERO Biotech LLC Nitrogen dioxide storage cassette

Also Published As

Publication number Publication date
JP2019131556A (ja) 2019-08-08
EP2713723B1 (en) 2018-09-12
WO2012166534A1 (en) 2012-12-06
JP2017165731A (ja) 2017-09-21
US11154210B2 (en) 2021-10-26
US20130309328A1 (en) 2013-11-21
AU2012262534A1 (en) 2013-12-12
EP2713723A1 (en) 2014-04-09
AU2012262534B2 (en) 2016-06-02
EP2713723A4 (en) 2015-03-25
CA2837341A1 (en) 2012-12-06
JP2014527025A (ja) 2014-10-09

Similar Documents

Publication Publication Date Title
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IN2014KN00996A (cg-RX-API-DMAC7.html)
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
EP4512470A3 (en) Methods of treating heart failure with cardiac sarcomere activators
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
IN2012DN06309A (cg-RX-API-DMAC7.html)
PH12014500386A1 (en) Combination treatment for hepatitis c
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
WO2012058585A3 (en) Treatment of heart failure with natriuretic peptides
WO2011127019A3 (en) Methods for treating respiratory viral infection
MX2014005895A (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2014012025A3 (en) Igf-1 proteins and therapeutic uses thereof
WO2018065917A3 (en) A synthetic pulmonary surfactant composition for treating lung conditions
WO2012040444A3 (en) Treatment of patients with incipient alzheimer's disease
MX2013012551A (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
UA64830U (ru) Способ лечения больных гастроезофагеальной рефлюксной болезнью в сочетании с хроническим обструктивным заболеванием легких
WO2012097311A3 (en) Intraluminal scaffold system and use thereof
UA53602U (ru) Способ возмещения кровопотери при политравме в условиях догоспитального этапа
UA62741U (ru) Способ профилактики респираторных осложнений после операции на легких и плевре с разными видами торакопластики
Liu Digestive tract haemorrhage in an elderly patient: case report
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513